Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.45 |
| ▸ | OGT | O15294 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DDO | Q99489 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10771946 | 0.91 | F2 (0.42) | ELANEF2CFDOGTHCAR2 | |
| SCHEMBL4509421 | 0.89 | F2 (0.49) | ELANEF2CFDOGTDAO | |
| SCHEMBL5265332 | 0.84 | F2 (0.41) | ELANEF2CFDOGTHCAR2 | |
| SCHEMBL10343102 | 0.83 | F2 (0.50) | ELANEF2CFDOGT | |
| SCHEMBL19628844 | 0.81 | F2 (0.47) | ELANEF2CFDOGTDAO | |
| SCHEMBL28766918 | 0.77 | HCAR2 (0.43) | F2CFDOGTHCAR2 | |
| SCHEMBL6008274 | 0.77 | BCHE (0.43) | ELANEDAOMEN1KMT2ADDO | |
| SCHEMBL15823883 | 0.77 | CYP1A2 (0.52) | ELANEF2CFDOGTDAO | |
| SCHEMBL28302703 | 0.75 | DAO (0.46) | ELANEF2CFDDAOMEN1 | |
| SCHEMBL619937 | 0.75 | F2 (0.52) | ELANEF2CFDOGTDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109338-B2 | For use in the prophylaxis and the treatment of Picornavirus and human rotavirus infections. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1380575-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6541470-B1 | Have a potent antiviral activity against picornaviruses and rotaviruses. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| EP-1081138-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MAVS, IRF3, EIF2AK2 | ELANE 3213/4885F2 4735/4885CFD 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.